Banmeet Anand, PhD
Dr. Banmeet Anand joined Juvena Therapeutics in October 2024 as Senior Vice President of Drug Development with more than 20 years of experience in the discovery and development of antibodies (naked, ADCs, fusion proteins and bi-specific), small molecules, and cellular therapies (NK-T, CAR-T). Dr. Anand most recently was Senior Vice President of Translational Medicine ay Harpoon Therapeutics (a subsidiary of Merck Inc.) where he led toxicology, pharmacology, biomarkers, non-clinical/clinical PK/PD, companion diagnostics including IND-enabling studies supporting Harpoon’s proprietary TriTAC biologics (T-cell engager) portfolio. Dr. Anand previously held management and scientific positions at Molecular Templates, NantKwest (ImmunityBio), Astellas (Agensys) and Genentech where he was involved in early and late development of multiple approved drugs such as RITUXAN®, PADCEV® and OCREVUS®. Dr. Anand received his PhD in Pharmaceutical Sciences and Chemistry from the University of Missouri-Kansas City.
Learn more about Banmeet
LinkedIn
